Date: Monday 24th – Wednesday 26th April 2023
Venue: Sage Gateshead, St Mary's Square, Gateshead NE8 2JR
ANTIRETROVIRALS: EFFICACY, INTERACTIONS & PHARMACOKINETICS
P001 Efficacy, Safety and Tolerability of Biktarvy in HIV1 infection: A Scoping Review
Ellen Peters, Brighton and Sussex Medical School, UK
P002 Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide
Chloe Orkin, Queen Mary University of London, UK
P003 Week 52 subgroup efficacy of lenacapavir in heavily treatment-experienced people with HIV
Cindy Elliott, Gilead Sciences Ltd, UK
P004 24-Month (24M) effectiveness and safety of bictegravir/emtricitabine/tenofovir Alafenamide (B/F/TAF) in treatment-naïve (TN) and treatmentexperienced (TE) people living with HIV in the BICSTaR study
Marta Boffito, Chelsea and Westminster Hospital, UK
P005 Switching to high genetic-barrier integrase inhibitors reduces drug-drug interactions in people living with HIV
Chhavi Nashier, Imperial College London, UK
P006 Successful implementation of a novel treatment strategy: challenges, outcomes and patient perspectives
Kate Holland, Walsall Healthcare NHS Trust, UK
P007 Outcome of National ARV Procurement, University Hospitals of Leicester
Iain Stephenson, University Hospitals of Leicester NHS Trust, UK
P008 A retrospective review to identify acceptability of doravirine containing regimens in our single centre cohort of people with HIV (PWH)
Gavin Marshall, Royal Free London NHS Foundation Trust, UK
P009 Switching to Biktarvy®: real world single centre outcomes over 3 years
Lisa King, Imperial College Healthcare Trust, UK
P010 Total lymphocyte and CD4+ T-cell count changes in participants receiving islatravir (0.25mg, 0.75mg, and 2.25mg once daily) and doravirine±lamivudine: post hoc analysis from a phase 2b dose-ranging study (P011)
Rima Lahoulou, MSD France, France
P011 Sequencing of low viral load HIV for drug resistance associated mutations
Anjna Badhan, Imperial College London, UK
P012 - WITHDRAWN Has switching off efavirenz-based antiretroviral therapy positively affected our patient cohort, with a focus on lipids and mental health outcome?
Pegah Soltanpoor, Kings College London, UK
P013 A multi-centre audit of changes to renal function and weight following a switch from tenofovir disoproxil fumarate to tenofovir alafenamide
Emily Boardman, The Northern Contraception, Sexual Health & HIV Service, UK
P014 Review of Protease inhibitor use in our single site clinic for people living with HIV (PLWH)
Pedro Simoes, Royal Free London NHS Foundation Trust, UK
P015 Effectiveness of dolutegravir + lamivudine in realworld studies in people with HIV-1 with M184V/I mutations: a systematic review and meta-analysis
Tristan Barber, Royal Free London NHS Foundation Trust, UK
P016 Characteristics and reasons for switch to Biktarvy in a large clinical cohort
Hao Gao, University College London Medical School, UK
P017 What influences acceptability of long-acting injectable ART and treatment setting: preliminary qualitative findings from the ILANA trial
Rosalie Hayes, Queen Mary University of London, UK
P018 Single centre review of rapid antiretroviral therapy initiation during the COVID-19 pandemic
Michael Ewens, Leeds Teaching Hospitals NHS Trust, UK
P135 5-year outcomes of bictegravir-emtricitabinetenofovir alafenamide (B-F-TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomised clinical trials
Chloe Orkin, Queen Mary University of London, UK
THEMED POSTER
TP01 Blueteq is not just about cost, it’s an opportunity to optimise antiretroviral therapy
Sinead Peare, Guy's and St Thomas' NHS Foundation Trust, UK
BASIC SCIENCE: IMMUNOLOGY, VIROLOGY & PATHOGENESIS
P019 Neutralising antibodies (NAbs) against SARSCoV-2 in BNT162b2 vaccine recipients with a history of advanced HIV infection: cPass as a simpler alternative to gold-standard tests
Alessandra Ruggiero, University of Verona, Italy
P020 Rapid HIV progression in patients with increased prevalence of unstable HLA-C variants
Alessandra Ruggiero, University of Verona, Italy
P021 Analysis of Broadly Neutralising Antibody Resistance in Adolescents and Young People living with HIV
Panagiota Zacharopoulou, University of Oxford, UK
BEHAVIOUR, TRANSMISSION AND PREVENTION
P022 Do we need to further Improve quality of care for those on pre-exposure prophylaxis (PrEP) against acquiring HIV infection: findings from a PrEP clinic
Ambika Puri, Walsall Manor Hospital, UK
P023 Self-sourcing of HIV pre-exposure prophylaxis (PrEP) amongst service users of Sexual Health London (SHL), a large, regional online postal sexually transmitted infection (STI) testing service
Laura Stewart, Chelsea and Westminster Hospital, UK
P024 The impact of policy support for HIV Pre-Exposure Prophylaxis use on the number of new HIV diagnoses among men who have sex with men: an interrupted time series analysis
Hongbo Jiang, Guangdong Pharmaceutical University, China
P025 HIV Pre-Exposure Prophylaxis use on a global scale among men who have sex with men: a systematic review and meta-analysis
Hongbo Jiang, Guangdong Pharmaceutical University, China
P026 Missed opportunities for Pre-Exposure Prophylaxis (PrEP) and outcomes of people acquiring HIV with previous or recent PrEP use
Stephanie Tyler, Guy's and St Thomas' NHS Foundation Trust, UK
P027 Using survey data to estimate the number of gay, bisexual and other men who have sex with men living with HIV at higher risk of mpox infection in England
Veronique Martin, UK Health Security Agency, UK
P028 Current PrEP provision does not align with women’s preferences: Early results from a cross-sectional survey investigating PrEP awareness, interest, and preferences among women in England
Melissa Cabecinha, University College London, UK
P029 Provision to diagnose, treat and prevent HIV in secure facilities of incarceration across the United Kingdom
Katie Humphries, NHS Lothian, UK
P030 A systematic review of qualitative research on recently acquired HIV
Emily Jay Nicholls, University College London, UK
P031 Quantifying re-engagement of people in HIV care after 12 months of non-attendance in outpatient clinic
Christina Nigrelli, St George's University Hospitals NHS Foundation Trust, UK
P032 Barriers to and facilitators of hepatitis C virus testing and disclosure among gay, bisexual and other men who have sex with men: findings from online focus groups
Nina Vora, University College London, UK
P033 Comparison between COVID-19 & monkeypox vaccine uptake in a diverse London HIV cohort
Alison Barbour, Croydon Sexual Health Centre, UK
P034 Urgent clinical need for reimbursed F/TAF PrEP in England: A single integrated sexual health service's (ISHS) experience of funding F/TAF PrEP post solid organ transplantation
Michael Ewens, Leeds Teaching Hospitals NHS Trust, UK
P035 Understanding barriers and facilitators to HIV care retention – a systematic review
Breda Patterson, Gilead Sciences Ltd, UK
CHILDREN AND PREGNANCY
P036 Setting the research agenda: involving mothers living with HIV in research on children born HIVfree in the UK
Laurette Bukasa, University College London Great Ormond Street Institute of Child Health, UK
P037 HIV vertical transmission in England: current challenges
Helen Peters, Integrated Screening Outcomes Surveillance Service (ISOSS), UK
P038 Current overview of paediatric follow-up of infants exposed to HIV in England
Kate Francis, Integrated Screening Outcomes Surveillance Service (ISOSS), UK
P039 Infant Postnatal Prophylaxis (PNP) following maternal viraemia during breastfeeding
Emily Lees, University of Oxford, UK
P040 Infant feeding choices in women living with HIV since 2019: reflections on real world data from an inner city tertiary HIV antenatal service
Eleanor Hamlyn, Royal Free Hospital, UK
P041 Population-level paediatric HIV surveillance in England: the current picture
Gabriela Toledo, University College London Great Ormond Street Institute of Child Health, UK
P042 A postnatal clinic for people living with HIV (PLWHIV), a specialist trainee led initiative to improve outcomes
Joseph Heskin, Chelsea and Westminster NHS Foundation Trust, UK
P043 Ethical considerations for non-disclosure of HIV status in pregnancy
Yasmin Walters, Chelsea and Westminster NHS Foundation Trust, UK
P044 'Don't forget the children' - even in a pandemic
Michael Ewens, Leeds Teaching Hospitals NHS Trust, UK
CO-MORBIDITIES, CO-INFECTIONS AND HIV/ART COMPLICATIONS
P045 Significant weight loss in people receiving metformin and dolutegravir
Hannah Alexander, North Middlesex University Hospital, UK
P046 Predictors of hepatitis B treatment response in people with HIV and HBV initiating treatment
Samm Kabagambe, Gilead Sciences Ltd, UK
P047 Common adverse events in clinical studies of people using lenacapavir for HIV treatment
Ricky Tsang, Gilead Sciences Ltd, UK
P048 Primary Effusion Lymphoma: a single-institution cohort study
Mark Bower, Centre for HIV Malignancy, UK
P049 Effect of low-dose oral vitamin d on bone mineral density changes in hiv patients: longitudinal prospective study for 6 years
Shyamalie Bopitiya, Coventry and Warwickshire Partnership Trust, UK
P050 Cerebrospinal fluid HIV RNA and viral nucleic acid detection in persons with HIV
Manraj Bawa, Imperial College London, UK
P051 Resolution of neuropsychiatric adverse events after switching to a doravirine-based regimen in the open-label extensions of the DRIVE-AHEAD and DRIVE-FORWARD trials
Rima Lahoulou, MSD France, France
P052 Factors associated with weight loss or stable weight after continuing or switching to a doravirine-based regimen
Rima Lahoulou, MSD France, France
P053 Associations between inflammatory profiles and multimorbidity burden among people living with HIV
Caroline A Sabin, University College London, UK
P054 Weight and body mass index changes in women receiving cabotegravir + rilpivirine long-acting or bictegravir in the SOLAR study
Parul Patel, ViiV Healthcare, Durham, USA
P055 Risk factors for hepatic steatosis in people living with and without HIV: Evidence from the POPPY cohort study
Alejandro Arenas-Pinto, University College London, UK
P056 Psychological wellbeing and sleep in human immunodeficiency virus (HIV)- a retrospective analysis of assessment and interventions within HIV services in the UK and Ireland (UKI)
Nicola Galbraith, Gilead Sciences Ltd, UK
P057 COVID-19 vaccination rates in people living with HIV in North East England
Ben Sayer, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK
P058 Co-morbidities in people living with HIV in the North-East who are unvaccinated against COVID-19: a descriptive study
Ben Sayer, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK
P059 Tackling Hepatitis B co-infection in PLHIV after COVID: an Audit and updated guidelines
Hannah Alexander, North Middlesex University Hospital, UK
P060 Clinical outcome of lopinavir/ritonavir as hiv second line treatment in single tertiary hospital in Malaysia
Kok Soon Lee, Hospital Sultanah Aminah, Johor Bahru, Malaysia
P061 A collaborative approach to the management of neurological conditions in people living with HIV
Kimiya Asjadi, Kings College Hospital, UK
P062 First description of Efavirenz as a cause of drug induced autoimmune hepatitis: compelling evidence from two cases
Amelia Oliveira, King's College Hospital, UK
P063 Sight-threatening mpox in people living with wellcontrolled and advanced HIV: two case reports of mpox blepharokeratoconjunctivitis with prolonged viral shedding
Tatiana Bovill Rose, St George's Hospital NHS Foundation Trust, UK
P064 A review of dolutegravir use and weight gain in a diverse HIV cohort in outer North-West London
Venkateshwaran Sivaraj, London North West University Healthcare NHS Trust, UK
P065 Re-framing how frailty is identified, diagnosed and managed among people living with HIV: exploratory perspectives from clinical practice
Tristan Barber, Royal Free London NHS Foundation Trust, UK
P066 The impact of the Covid-19 pandemic on cervical screening and outcomes for women living with HIV
Dona Rimanishta, Brighton and Sussex Medical School, Brighton, UK
HIV TESTING, EPIDEMIOLOGY AND SURVEILLANCE
P067 HIV Partner notification during the Pandemic - An audit of new diagnoses HIV diagnoses at a local clinic between Jan 2020 – Feb 2022
Vafie Sheriff, St Georges University of London, UK
P068 Audit of missed opportunities in people diagnosed late with HIV and establishment of a review and feedback process for new late diagnoses
Clemency Nye, Cardiff and Vale University Health Board, UK
P069 Implementing a late diagnosis review protocol for HIV across the southeast of England with a public health perspective: lessons for national roll-out
Lucy Lynch, UK Health Security Agency, UK
P070 Factors associated with severe SARS-COV-2 infection in people of black ethnicities living with HIV in the UK
Zoe Ottaway, Kings College Hospital NHS Foundation Trust, UK
P071 Previous HIV testing rates amongst heterosexuals diagnosed HIV positive through Sexual Health London (SHL), an online postal sexually transmitted infection testing (STI) service
Gemma McDonald, Chelsea and Westminster Hospital, UK
P072 Mortality among people with HIV in the UK in 2021: findings from the National HIV Mortality Review
Ammi Shah, UK Health Security Agency, UK
P073 Viral suppression, linkage to care, and outcomes in those previously diagnosed abroad
James Lester, UK Health Security Agency, UK
P074 Auditing BHIVA 2020 HIV testing guidelines in primary care in an area of extremely high HIV seroprevalence: A cross-sectional, regional questionnaire
Simisola Agunbiade, Chelsea and Westminster Hospital
P075 An audit of new diagnoses of HIV in a deprived local authority – are we detecting HIV too late?
Chevonne van Rhee, Public Health Sandwell Metropolitan Borough Council, UK
P076 Progress towards ending HIV transmission in England by 2030
Veronique Martin, UK Health Security Agency, UK
P077 Trends in the number of people living with transmissible HIV in England, 2019–2021
Veronique Martin, UK Health Security Agency, UK
P078 HIV knowledge survey in a district hospital
Wai Lin Htun, Blackpool Teaching Hospital NHS Foundation Trust, UK
P079 New diagnoses of HIV through multi-centre emergency department opt-out HIV testing
Farnaz Dave, North Manchester General Hospital, UK
P080 Higher late diagnosis among people diagnosed with HIV through emergency department opt-out testing programs at Ealing, Brent, and Harrow boroughs of London
Venkateshwaran Sivaraj, London North West University Healthcare NHS Trust, UK
P081 Nurse led management of HIV results from Emergency Department opt-out testing
Jessica Pinto, Royal Free London NHS Foundation Trust, UK
P082 Using implementation science to support the adoption of routine HIV testing in a suburban Emergency Department
Olubanke Davies, Epsom & St Helier University Hospitals NHS Trust, UK
P083 Risk factors for HIV outcomes among people newly diagnosed with HIV in England
Andres Felipe Mora-Salamanca, University College London, UK
P084 HIV outcomes differences between gay and bisexual Latin American migrants and other gay and bisexual populations in England
Andres Felipe Mora-Salamanca, University College London, UK
P085 An assessment of a District General Hospital’s (DGH) compliance to HIV screening guidelines, and an analysis of barriers to routine testing. Implementation of interventions towards improving routine screening
Chidera Chukwufumnanya Aligbe, Northern Care Alliance, UK
P086 Clinical epidemiology of COVID-19 in black people with HIV in South London, UK
Zoe Ottaway, Kings College Hospital NHS Foundation Trust, UK
P087 HIV testing in community settings in England: results from the 2021 survey
Neil Mackay, UK Health Security Agency, UK
P088 UKHSA engagement data: a useful tool for HIV centres to identify patients not in care
Hannah Alexander, North Middlesex University Hospital, UK
P089 Prevalence and presentations of HIV in asylum seekers in the London borough of Hounslow
Alissa Amrose, West Middlesex University Hospital, UK
P090 Comparing short-term mortality between people with and without HIV admitted to the intensive care unit, 2000-2019
Caroline A. Sabin, University College London, UK
P091 How use of cut-off index (COI) helps clinicians manage reactive HIV test results that arise from service users accessing Sexual Health London (SHL), a regional STI/HIV postal testing service
Sophie Jones, Chelsea and Westminster NHS Trust, UK
P092 Campaigning for HIV/AIDS prevention: a community-led approach to widen access and uptake of HIV testing
Alessandro Ceccarelli, Fast Track Cardiff & Vale, UK
P093 Service evaluation of the clinical impact of the blood bottle shortage on opt-out HIV testing in sexual health services and the uptake of online HIV self-testing
Jasmine Limbu, Cardiff University, UK
THEMED POSTER
TP02 Opportunities to improve opt-out blood-borne virus screening in two large London Emergency Departments
Cassandra Fairhead, Royal Free London NHS Foundation Trust, UK
PSYCHOSOCIAL ISSUES AND QUALITY OF LIFE
P094 Patients living with HIV (PLWH) not in care – what are the barriers to accessing treatment?
Ayoma Ratnappuli, King's College Hospital, UK
P095 Towards positive practice - people living with HIV and experiences of primary care
Joshua Wharton, George House Trust, UK
P096 Fifty Over 50 – a collection of individual reflections on growing older with HIV
Mike Newman, Merck Sharp & Dohme UK, UK
P097 “Attitudes hadn't changed as much as I'd thought”: Experiences of HIV Stigma in the North East of England
Kate Reilly, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
P098 Addressing internalised stigma in HIV clinics - a London Fast-Track Cities Initiative (FTCI) project
Harun Tulunay, Positively UK
P099 Measuring what matters: how do we assess sleep in HIV care?
Michelle Croston, University of Nottingham, UK
P100 - WITHDRAWN “I’m sorry I didn’t attend; I was getting on with my life.” A study of issues affecting people living with Human Immunodeficiency Virus (HIV) from engaging in care
Julie-Anne Field, Outpatients East Barking Hospital, UK
P101 Social prescribing for people living with HIV
Emily Edwards, University of Aberdeen, UK
P102 ‘Start Making Sense’: a qualitative exploration of a trauma psychoeducation group for people living with HIV
Kate Reilly, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK
P103 How did the COVID pandemic impact anxiety and health anxiety in women living with HIV?
Joanne Mc Carthy, Positive East, UK
P104 Stitch Sisters – Psychology outside the box
Joanne McCarthy, Positive East, UK
P105 Addressing loneliness and dietary needs during the COVID-19 pandemic: experiences of people living with HIV receiving support from a small HIV support organisation
Gary Pargeter, Lunch Positive, UK
SERVICE DEVELOPMENT, EDUCATION & TRAINING
THEMED POSTERS
TP03 Patient evaluation of Klick, a technology enabled, nurse delivered HIV outpatient pathway
Caroline Rae, Chelsea and Westminster Hospital, London, UK
TP04 An innovative, patient centered approach to delivery of long-acting injectable antiretroviral therapy to people living with HIV using pre-existing outpatient parenteral antimicrobial therapy (OPAT) services
Bazga Ali, Public Health Wales, Cardiff, UK
TP05 Addressing the Workforce Challenge: Role of the Advanced Pharmacist Practitioner (APP)
Hasan Mohammed, Chelsea & Westminster Hospital NHS Foundation Trust, UK
TP06 Integrating peer support within NHS clinics - a London Fast-Track Cities Initiative (FTCI) project
Garry Brough, Positively UK, London, UK
P107 Audit outcomes of nurse delivered care within Klick, a technology enabled, outpatient pathway for people living with HIV (PLWH)
Rebecca Wilkins, Chelsea and Westminster Hospital, UK
P108 Latent TB screening in people living with HIV within Rochdale, Greater Manchester
Siew Yan Teo, HCRG Care Group - ORB, UK
P109 An audit of uptake of flu, COVID-19 and pneumococcal vaccines in a cohort of people living with HIV
Nicoll Butter, University of Aberdeen, UK
P110 Retaining patients in care: a multidisciplinary team (MDT) approach for patients who do not attend clinic (DNA) on the day
Goli Haidari, Guy's & St Thomas' NHS Foundation Trust, UK
P111 The use and utility of toolkits in supporting cabotegravir + rilpivirine long-acting implementation in the CARISEL (Cabotegravir And Rilpivirine Implementation Study in European Locations) study
Rekha Trehan, ViiV Healthcare, UK
P112 ‘More taboo than talking about drugs’ - a qualitative assessment of the sexual health needs of people who inject substances in Greater Glasgow and Clyde
Claire Kofman, Waverley Care, UK
P113 Knowledge of HIV and attitudes towards people living with HIV amongst hospital healthcare workers
Linda Cheyenne Vaccari, Royal Free London NHS Foundation Trust, UK
P114 Outpatient parenteral antimicrobial therapy (OPAT) service delivery of long-acting antiretrovirals – clinical staff and patient-reported outcome measures (PROMs)
Thomas George, Cardiff and Vale University Health Board, UK
P115 Examining HPV related cancer screening and vaccination rates amongst women in a large HIV service
Chloe White, University College London Medical School, UK
P116 Examining HPV related cancer screening and vaccination rates amongst MSM in a large HIV service
Chloe White, University College London Medical School, UK
P117 Long Acting injectable Antiretrovirals (LAI-ARVs) – Multidisciplinary team (MDT) outcomes from a large London HIV service
Bhavna Halai, Guy's and St Thomas' NHS Foundation trust, UK
P118 Experiences of Establishing a Long-Acting Injectable (LAI) Anti-Retroviral (ARV) Clinic
Bhavna Halai, Guy's and St Thomas' NHS Trust, UK
P119 The stable patient pathway (SPP) one year on - reduced monitoring and patient initiated follow up (PIFU) for stable patients in a London HIV outpatient department
Zareena Mahomed, Guy's & St. Thomas' NHS Foundation Trust, UK
P120 User experience of an in-clinic pre-exposure prophylaxis (PrEP) service
Eliot Hurn, Lewisham and Greenwich NHS Foundation Trust, UK
P121 A three-cycle quality improvement project to improve HIV testing for patients presenting with indicator conditions to acute medicine in Gateshead, UK
Alexander Martin, Gateshead Health NHS Foundation Trust, UK
P122 Is hepatitis c screening worthwhile? an investigation into hepatitis c screening in cumbria's sexual health clinics
Jason Niblett, North Cumbria Integrated Care NHS Trust, UK
P123 What happens after reengagement? Outcomes of PLWH linked back into care through a dedicated SE London program
Kate Childs, King's College Hospital NHS Trust, UK
P124 A collaborative approach to research study recruitment in PLWH during the SARS CoV-2 pandemic
Katherine Spears, Royal Free London NHS Foundation Trust, UK
P125 How many patients will require Tenofovir Alafenamide (TAF) based HIV pre-exposure prophylaxis?
Rebecca Coltart, University of Glasgow, UK
P126 Quality of transfer letters for patients moving HIV providers in the UK
Michael Ward, Calderdale and Huddersfield NHS Trust, UK
P127 Cost-effectiveness of switching antiretroviral therapy to British HIV Association recommended regimens
Aidan Ireland, South Tees Hospitals NHS Foundation Trust, UK
P128 What is the new normal? Frequency of monitoring after COVID-19
Brendan Payne, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK
P129 Post-exposure prophylaxis for sexual exposure (pepse) prescriptions in the era of pre-exposure prophylaxis (prep)
Harsha Moolchandani, MPFT, UK
P130 Is the switch worth it? How changing from noncommissioned antiretrovirals has affected cost and pill burden in a single centre
Theodora Voitcu, The Newcastle upon Tyne Hospitals Foundation Trust, UK
STI, REPRODUCTIVE HEALTH, CONTRACEPTION & SEXUAL DYSFUNCTION
P131 Review of the characteristics of Syphilis cases over 10 years in an inner-city urban cohort
Wai Lin Htun, Blackpool Teaching Hospital NHS Foundation Trust, UK
P132 Characteristics and outcomes of Mpox infection in people living with Human Immunodeficiency Virus (PLWHIV)
Anna Garder, The Northern Integrated Contraception, Sexual Health and HIV Service, UK